Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study
Portfolio Pulse from Vandana Singh
Novartis AG has released positive interim results from its Phase 3 ALIGN study of atrasentan, a drug for IgA nephropathy (IgAN), a major cause of chronic kidney disease. The drug demonstrated a significant reduction in proteinuria in patients with IgAN. Novartis plans to submit an application for possible accelerated approval in the US in 2024. The company's shares are up 1.68% at $93.82.
October 30, 2023 | 3:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' positive interim results for its kidney disease drug atrasentan could lead to accelerated approval in the US, potentially boosting its stock.
The positive results from the Phase 3 study of atrasentan indicate a high likelihood of approval for the drug. This could lead to increased revenues for Novartis, which would likely have a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100